Natural antifungal agent, significantly inducing lipid peroxidation, activating the antioxidant enzymes, and exhibiting effective activity against F. solani (EC50 = 10.56 µM)

HA-9104 is a specific small molecule inhibitor of E2 conjugating enzyme UBE2F with IC50 of 33.29 uM for inhibition of cullin-5 neddylation, abrogates UBE2F-NEDD8 thioester formation and inhibits cullin-5 neddylation.

QAF-805 (QAF805) is a potent, dual adenosine-A2B receptor and adenosine-A3 receptor antagonist with Ki of 3.4 nM (A2B).

Novel, systemically active kynurenine aminotransferase 2 (KAT2) inhibitor, significantly decreased escape latency in the Morris water maze, indicating improved performance in spatial and contextual memorynovel

Alprenolol HCl, or alfeprol, alpheprol, and alprenololum (Gubernal, Regletin, Yobir, Apllobal, Aptine, Aptol Duriles), is a non-selective beta blocker as well as 5-HT1A receptor antagonist, used in the treatment of angina pectoris. It is no longer marketed by AstraZeneca, but may still be available from other pharmaceutical companies or generically.

A potent and selective inhibitor of mitochondrial Na+/Ca2+ exchanger mNCX with neuroprotective activity. It was shown to reduce Ca2+ efflux from the mitochondria to the cytosol with an EC50 value of 690 nM and was shown to protect against Ca2+ overload an

PF 6260933 is a potent, selective and orally bioavailable MAP4K4 inhibitor with kinase IC50 of 3.7 nM, cell IC50 of 160 nM.

Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. It reduces glucose and body weight, and has the potential to be used in Type 2 diabetes mellitus (T2DM) research.

GNE-684 is a potent, cross-species, specific RIP1 kinase (RIPK1) inhibitor with IC50 of 21, 189 and 691 nM for human, mouse and rat RIP1, respectively.

AP30663 is a KCa2 channel inhibitor that can be used for the study of atrial fibrillation[1].

CVN766 (CVN 766) is a potent, exquisitely selective orexin 1 receptor (OX1R) antagonist with IC50 of 8 nM, 1000-fold selective over OX2R.

MZ-101 is a potent, selective inhibitor of glycogen synthase 1 (GYS1) with IC50 of 41 nM (human GYS1), with no inhibition against GYS2.

NT-0249 is an orally active NLRP3 inhibitor. NT-0249 has anti-inflammatory activity[1]

CRN04894 is a highly potent, selective, orally available melanocortin 2 receptor (MC2R antagonist) antagonist with Ki of 2.1 nM.

GLPG2737 is a potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector.

NMD670 is an orally bioavailable skeletal muscle-specific chloride ion channel (ClC-1) inhibitor. NMD670 showed to restore muscle function in rat models of myasthenia gravis (MG).

BAY-850 (BAY 850, BAY850) is a potent, isoform selective, cellularly active ATAD2 bromodomain inhibitor with binding IC50 of 166 nM in TR-FRET assay.

H3B8800 is an orally available splicing modulator that targets spliceosome SF3b complex containing either WT or mutant SF3B1 (binding IC50 of 0.3-2 nM),demonstrates dose-dependent inhibition of both canonical splicing and aberrant splicing induced by mutant SF3B1 in in vitro assays of biochemical splicing, induces lethality in spliceosome-mutant cancer cells.. H3B-8800 potently and preferentially kills spliceosome-mutant epithelial and hematologic tumor cells.

HM43239 is an orally active small molecule inhibitor of FLT3 that selectively inhibits not only FLT3 wild type, ITD mutants or TKD mutations, but also FLT3 ITD/TKD double mutations. HM43239 directly inhibits the kinase activity of FLT3 as a reversible Type I inhibitor and effectively modulates downstream p-STAT5 and p-ERK. HM43239 also demonstrated inhibition of SYK, JAK1/2 and TAK1, known to be involved in tumor cell proliferation and/or differentiation HM43239 monotherapy induced dose-dependent regression of tumor growth in FLT3 wild-type and FLT3 mutated leukemia cancer cell line.

UNC-1679 (UNC1679) is a potent and selective small molecule chemical probe of a methyl-lysine reader protein L3MBTL3 with Ki of 0.35 uM.

DOPE-PEG-Mal (MW 2000) is a phospholipid polyPEG which can be used to prepare liposomes or nanoparticles. It is also reactive with thiol at pH 6.5 tp 7.5 to form a stable thioether bond.

Vamorolone (VBP-15) is a dissociative steroidal compound, reduces NF-κB-mediated cytokine expression in vitro, alsp reduecs glucocorticoid-mediated side-effects when compared to dexamethasone in vivo.

B23&" is a phospholipid. Phospholipids have good biocompatibility and significant amphiphilic characteristics, making them the main and suitable dosage form or excipient in drug formulations, thereby achieving better therapeutic effects. "&B23&"can be used in drug delivery research.

B19&" is a phospholipid. Phospholipids have good biocompatibility and significant amphiphilic characteristics, making them the main and suitable dosage form or excipient in drug formulations, thereby achieving better therapeutic effects. "&B19&"can be used in drug delivery research."

Boc-Val-Cit-PAB is a linker for Antibody-Drug-Conjugation (ADC). The Val-Cit will specifically be cleaved by catepsin B. As this enzyme is only present in the lysosome the ADC payload will be release only in the cell. The Boc group can be deprotected under acidic conditions to generate a free amine group.

A drug-linker conjugate for antibody-drug conjugate by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the cleavable peptide SuO-Val-Cit-PAB..

B40&" is a phospholipid. Phospholipids have good biocompatibility and significant amphiphilic characteristics, making them the main and suitable dosage form or excipient in drug formulations, thereby achieving better therapeutic effects. "&B40&"can be used in drug delivery research."

DPPE-MPEG 2000 (1,2-DPPE-MPEG(2000)) is a PEG-modified lipids. DPPE-MPEG 2000 can reduce the nonspecific adsorption of protein and prolong circulation time in vivo.

DOPE-mPEG (MW 1000) is a phospholipid. Phospholipids have good biocompatibility and significant amphiphilic characteristics, making them the main and suitable dosage form or excipient in drug formulations to achieve better therapeutic effects. DOPE-mPEG (MW 1000) can be used in drug delivery research.

PESTAHIVIN is a cell adhesion molecule inhibitor. HUN-7293 selectively inhibits the expression of three cell adhesion molecules (VCAM-1, ICAM-1 and E-selectin) (IC50=1-24 nM). HUN-7293 can be used in the study of inflammatory and autoimmune diseases characterized by overexpression of cell adhesion molecules.